In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HepaVec AG

Division of Evotec SE

Latest From HepaVec AG

Neuer Markt Drives German Shopping Spree

Capitalizing on their hefty valuations, German public biotechs are going on a shopping spree, swapping stock for other companies and thereby creating broader platforms of technologies and in some cases clinical pipelines. In their zest for turning their paper into harder industrial assets, German biotechs are showing themselves far more aggressive than the majority of their American and British counterparts.
BioPharmaceutical Business Strategies

HepaVec AG

With technology licensed from the Max Planck Society, HepaVec is developing liver-specific viral vector systems for human gene therapy. Also liver tissue engineering.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Germany
  • Parent & Subsidiaries
  • Evotec SE
  • Senior Management
  • Herbert Stadler, PhD, CEO
    Heidemarie Rohdewohld, PhD, COO
  • Contact Info
  • HepaVec AG
    Phone: (49) 30 9489 2282
    Robert-Rossle-Strasse 10
    Berlin, D-13122